Answers are grounded in this paper and cite their sources.
Background/Objectives: Azathioprine (AZA) remains a key maintenance therapy in autoimmune hepatitis (AIH), but the role of pharmacogenetic testing and thiopurine metabolite monitoring in routine clinical practice is not fully established. We aimed to characterize thiopurine metabolite profiles according to biochemical response and TPMT genotype and to assess how therapeutic drug monitoring (TDM) informs treatment decisions in adults with AIH. Methods: We conducted a retrospective single-center observational study including adults with probable or definite AIH treated with AZA and with at least one erythrocyte 6-thioguanine nucleotide (6-TGN) and 6-methylmercaptopurine (6-MMP) measurement. Complete biochemical response (CBR) was defined as the normalization of transaminases and IgG. TPMT genotyping was performed according to local practice. Results: Among 112 patients (67% female; median age 55 years), TPMT genotype was available in 96, including seven (7.3%) TPMT*1/3A heterozygotes. Heterozygotes had higher 6-TGN concentrations and virtually undetectable 6-MMP despite lower AZA doses. The median 6-TGN was 386 pmol/8 × 108 RBC. AZA dose and TPMT*1/*3A genotype were independently associated with higher 6-TGN concentrations (β = +77 pmol/8 × 108 RBC per 0.5 mg/kg/day, p = 0.035; and β = +290 pmol/8 × 108 RBC, p = 0.004, respectively). Single-point 6-TGN concentrations were not associated with CBR. TDM was followed by treatment modification in 38 patients (34%), including dose adjustment, treatment switching, or the identification of non-adherence. No AZA-related myelotoxicity was identified. Conclusions: Single-point 6-TGN concentrations did not discriminate biochemical response, supporting interpretation in a clinical context rather than reliance on fixed thresholds. TDM provided clinically actionable information, while TPMT genotype identified a distinct metabolite profile associated with higher 6-TGN exposure at lower AZA doses. Together, these data support individualized interpretation of pharmacogenetic and metabolite information in AIH.
No takes yet. Share an insight, caveat, or question.
Julian et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: